uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics
uniQure N.V. - Ordinary Shares (QURE)
Today's Latest Price: $60.64 USD
2.95 (-4.64%)
Updated Feb 21 4:00pm
Add QURE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
QURE Stock Summary
- With a price/sales ratio of 484.39, uniQure NV has a higher such ratio than 99.28% of stocks in our set.
- With a year-over-year growth in debt of 245.79%, uniQure NV's debt growth rate surpasses 92.91% of about US stocks.
- Revenue growth over the past 12 months for uniQure NV comes in at -48.91%, a number that bests only 3.78% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to uniQure NV, a group of peers worth examining would be CRNX, TOCA, ARQL, ADAP, and CNCE.
- QURE's SEC filings can be seen here. And to visit uniQure NV's official web site, go to www.uniqure.com.
QURE Daily Price Range
QURE 52-Week Price Range
QURE Stock Price Chart More Charts
QURE Price/Volume Stats
| Current price | $60.64 | 52-week high | $82.49 |
| Prev. close | $63.59 | 52-week low | $36.20 |
| Day low | $60.37 | Volume | 251,100 |
| Day high | $63.74 | Avg. volume | 455,477 |
| 50-day MA | $66.68 | Dividend yield | N/A |
| 200-day MA | $59.94 | Market Cap | 2.65B |
uniQure N.V. - Ordinary Shares (QURE) Company Bio
uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.
Top Stories View All
Best & Worst Performing Stock Industries for February 21, 2020
Best & Worst Performing Small Cap Stocks for February 21, 2020
Best & Worst Performing Mid Cap Stocks for February 21, 2020
Best & Worst Performing Large Cap Stocks for February 21, 2020
Best & Worst Performing Mega Cap Stocks for February 21, 2020
View All Top Stories
Loading social stream, please wait...